glp 1 agonist oral or injection fda approved A new GLP-1 option is now part of obesity medicine FDA just approved orforglipron (Foundayo),

The GSH/GSSG ratio represents the balance between the reduced (active) and oxidized forms of glutathioneIn a healthy cell, this ratio is greater than 100:1 in favor of GSH

& Liu, F

High NADH/NAD+ and low GSH/GSSG ratios harm mitochondrial metabolism and lead to insulin resistance

Share your experience in the comments below

I think were going to go in the next like 12 to 18 months from these two main [injection] options from Novo Nordisk and Eli Lilly to half a dozen options in this class of medicines, Drucker says

Yang, Y., Xu, J., Zhou, J., Xue, J., Gao, J., Li, X., Sun, B., Yang, B., Liu, Z., Zhao, Z., Luo, Q., Zeng, Q., Zheng, L., & Xiong, C